Clinical trial · no report yet · Phase 3
PRIMORDIUM
A Study of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients With Hormone-Sensitive Prostate Cancer
- NCT04557059 ↗
- Active not recruiting
- Janssen Pharmaceutica N.V., Belgium
- 16 commentary sources found
- Standard
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Commentary we found
Podcasts, YouTube videos and X posts in our index that name this trial. A report screens them, searches for more and cites what clinicians said when it is built.
| Channel | Found | |
|---|---|---|
| YouTube | 7 | |
| Podcasts | 6 | |
| X threads | 3 |
The trial
ClinicalTrials.gov- Official title
- A Randomized, Controlled, Multicenter, Open-label Study to Investigate the Efficacy and Safety of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients With Hormone-Sensitive Prostate Cancer, Assessed by PSMA-PET With an Observational Cohort
- Phase
- Phase 3
- Status
- Active not recruiting
- Conditions
- Prostatic Neoplasms
- Interventions
- Radiotherapy; LHRHa; Apalutamide
- Arms
- Interventional Cohort (Group 1): RT+ LHRHa · Active comparator
- Interventional Cohort (Group 2): RT+LHRHa + Apalutamide · Experimental
- Observational Cohort(Group3) PSMA-PET Negative Participants · No intervention
- Enrollment
- 691
- Primary outcomes
- Prostate specific Membrane Antigen-Positron Emission Tomography (PSMA-PET) Metastatic Progression-free Survival (ppMPFS)
- Sponsor
- Janssen Pharmaceutica N.V., Belgium
- Start
- Nov 12, 2020
- Primary completion
- Aug 27, 2029 (estimated)
- Results posted
- No
- Registry record
- NCT04557059 · updated Sep 25, 2026